接受氟达拉滨与美法仑减低强度预处理患者碘他拉酸清除率与非复发死亡的关系
该研究纳入109例接受氟达拉滨与美法仑减低强度预处理异基因造血干细胞移植的患者,评估实测肾小球滤过率(mGFR)与非复发死亡(NRM)的关系。mGFR<65 mL/min/1.73 m2预测总体NRM、1年感染发生率显著升高及2年生存率显著降低,而基于肌酐的估算GFR与移植后结局无相关性。
要点
- mGFR<65 mL/min/1.73 m2预测总体NRM风险升高(HR 2.13)。
- mGFR<65 mL/min/1.73 m2预测1年感染风险升高(HR 2.63)。
- 基于肌酐的eGFR与移植后结局无相关性。
核心结论
- mGFR是评估异基因HSCT患者清除率的有前景方法,可能优于标准基于肌酐的eGFR策略。
研究设计与样本
- 研究纳入109例接受氟达拉滨与美法仑减低强度预处理后行异基因造血干细胞移植的患者,评估mGFR与NRM的关联。
主要发现
- mGFR<65 mL/min/1.73 m2预测1年感染发生率显著升高(HR 2.63;95%CI 1.54-4.55;P<0.001)。
- mGFR<65 mL/min/1.73 m2还与2年生存率显著降低相关(P=0.019)。
- 通过eGFR和估算肌酐清除率评估的肾功能与移植后结局无相关性。
临床怎么用
- 作者认为mGFR是评估异基因HSCT患者清除率的有前景方法,可能优于标准基于肌酐的eGFR策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The reduced-intensity conditioning regimen, fludarabine and melphalan, is frequently used in allogeneic hematopoietic stem cell transplantation (HSCT). Melphalan and the active metabolite of fludarabine, F-ara-A, are excreted via the kidneys. Existing methods to assess clearance in this setting are based on serum creatinine, which has known limitations for glomerular filtration rate (GFR) estimation in patients with malignancy. Measured GFR (mGFR) may better predict drug dosing to mitigate toxicity and increase the chances of successful engraftment. The primary objective of this study was to assess the association between mGFR and risk for nonrelapse mortality (NRM) in patients who have undergone allogeneic HSCT receiving conditioning with fludarabine and melphalan. In the 109 included patients, mGFR <65 mL/min/1.73 m2 predicted a significantly higher rate of overall NRM (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.03-4.35; P = 04) and 1-year incidence of infection (HR, 2.63; 95% CI, 1.54-4.55; P < .001) in addition to a significantly lower 2-year survival (P = .019). Kidney function estimated via estimated GFR (eGFR) and estimated creatinine clearance did not correlate with posttransplant outcomes. These results suggest that mGFR is a promising approach for assessing clearance in patients who have undergone allogeneic HSCT and may be preferred to standard creatinine-based eGFR strategies.
引用
- Kutzke JL, Merten JA, Pawlenty AG, et al. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Blood Adv. 2022. PMID: 35522968. doi:10.1182/bloodadvances.2021006395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。